Achaogen to Present at Needham & Company's 17th Annual Healthcare Conference


Press Release

<< Back
March 14, 2018 at 8:01 AM EDT

Achaogen to Present at Needham & Company's 17th Annual Healthcare Conference

-- Company presentation scheduled for March 27, 2018 --

SOUTH SAN FRANCISCO, Calif., March 14, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the Company will present at Needham & Company's 17th Annual Healthcare Conference taking place March 27 to 28, 2018 in New York. Achaogen management will present at 2:00 p.m. Eastern Time on Tuesday, March 27th, 2018.

A live audio webcast of the presentation will be available in the "Investors" section of Achaogen's website, www.achaogen.com. A replay of the presentation will be archived on the website for 30 days following the conference.

About Achaogen
Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. The Food and Drug Administration has granted plazomicin Breakthrough Therapy designation for the treatment of bloodstream infections caused by certain Enterobacteriaceae in patients who have limited or no alternative treatment options. The Company's second product candidate is C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination for the treatment of serious bacterial infections due to ESBL-producing Enterobacteriaceae. Achaogen's plazomicin program has been funded, and its C-Scape program is funded, in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA). Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections and additional disease areas. All product candidates, including plazomicin, are investigational only and have not been approved for commercialization. For more information, please visit www.achaogen.com.

Source: Achaogen, Inc. (NASDAQ:AKAO)

Investor Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
arr@lifesciadvisors.com

Media Contact:
Denise T. Powell
Red House Consulting, LLC
dpowell@achaogen.com